GSK announces positive topline data on co-administration of …
WEB1 day ago · GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) when co-administered with SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted), both AS01-adjuvanted …
GSK (LSE:GSK) Poised for Growth with Strong Sales, Strategic …
WEB1 day ago · GSK(LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a robust 13% sales growth and strategic innovations in R&D, contrasted with ...
New Novartis data in relapsing MS reinforce benefits of …
WEB1 day ago · Novartis obtained rights for ofatumumab from GlaxoSmithKline in all indications, including RMS, in December 2015 11. Kesimpta has been approved for the treatment of relapsing forms of multiple sclerosis in over 90 countries worldwide with more than 100,000 patients treated as of August 2024 6,7,12 .
Press releases - GSK
WEBGSK receives US FDA Breakthrough Therapy Designation for its B7-H3-targeted antibody-drug conjugate in relapsed or refractory extensive-stage small-cell lung cancer.
GSK's experimental drug shows promise in reducing severe …
WEBMay 21 (Reuters) - GSK's (GSK.L) experimental drug met its primary goal of reducing asthma attacks in a late-stage trial, marking a bright spot for a treatment that the British drugmaker expects to...
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. This is the first …
GSK News
WEBStay updated on the latest news from GSK, a global healthcare company with innovative medicines, vaccines and consumer products.
Jemperli (dostarlimab-gxly) plus chemotherapy approved in the …
WEBJul 31, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair …
GSK to acquire clinical-stage biopharmaceutical company …
WEBMay 31, 2022 · GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones. Proposed acquisition provides access to next-generation 24-valent pneumococcal vaccine candidate in phase II development and highly innovative, MAPS TM technology.
GSK presents promising new data for bepirovirsen, an …
WEBJun 25, 2022 · GSK plc today announced promising interim results from the B-Clear phase IIb trial showing that bepirovirsen, an investigational antisense oligonucleotide treatment for hepatitis B, reduced levels of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA after 24 weeks’ treatment in people with chronic hepatitis B (CHB).